•  
  •  
  •  
  •  

2025-09-28 00:28:54

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Anand Rayons Ltd receives approval for STAPII trademark
  • IRFC extends funding support to PVUNL for INR 3,388.51 crore
  • Zaggle Prepaid Ocean Services Ltd enters into agreement with IDFC First Bank Ltd
  • PNG Jewellers expands National Footprint, Celebrates Lucknow's Cultural Legacy with Maiden Store Launch
  • Interarch strengthens presence in Multi-Storey Steel Buildings with new plant in Attivaram, Andhra Pradesh

Keywords Selected:  INE326A01037

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
  • Lupin receives approval from U.S. FDA for Lenalidomide Capsules
  • Lupin receives 6 observations from USFDA for Nagpur Injectable facility
  • USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility
  • Lupin receives U.S. FDA approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • Lupin announces licensing deal for Ranibizumab Biosimilar
  • Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States
  • Lupin receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
  • Lupin receives Form 483 with 3 observations from USFDA for Pithampur Unit-3
  • Lupin achieves GMP Certification from TGA Australia for Dabhasa API Facility
  • Lupin receives Form 483 with 4 observations from USFDA for Pithampur Unit-2
  • Lupin launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States
  • Lupin receives approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
  • Lupin carves out LupinLife Consumer Healthcare
  • Lupin launches Prucalopride tablets in the United States
  • Lupin receives approval from U.S. FDA for Prucalopride Tablets
  • Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Punita Lal Joins Lupin Board as Additional Director
  • Lupin receives approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg

Latest Post

  • Anand Rayons Ltd receives approval for STAPII trademark
  • IRFC extends funding support to PVUNL for INR 3,388.51 crore
  • Zaggle Prepaid Ocean Services Ltd enters into agreement with IDFC First Bank Ltd
  • PNG Jewellers expands National Footprint, Celebrates Lucknow's Cultural Legacy with Maiden Store Launch
  • Interarch strengthens presence in Multi-Storey Steel Buildings with new plant in Attivaram, Andhra Pradesh


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024